William E Smiddy1. 1. Bascom Palmer Eye Institute, PO Box 016880, Miami, FL 33101-6880, USA. wsmiddy@med.miami.edu
Abstract
PURPOSE: To relate costs and treatment benefits for diabetic macular edema (DME), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO). DESIGN: A model of resource use, outcomes, and cost-effectiveness and utility. PARTICIPANTS: None. METHODS: Results from published clinical trials (index studies) of laser, intravitreal corticosteroids, intravitreal anti-vascular endothelial growth factor (VEGF) agents, and vitrectomy trials were used to ascertain visual benefit and clinical protocols. Calculations followed from the costs of 1 year of treatment for each treatment modality and the visual benefits as ascertained. MAIN OUTCOME MEASURES: Visual acuity (VA) saved, cost of therapy, cost per line saved, cost per line-year saved, and costs per quality-adjusted life years (QALYs). RESULTS: The lines saved for DME (0.26-2.02), BRVO (0.74-4.92), and CRVO (1.2-3.75) yielded calculations of costs/line of saved VA for DME ($1329-$11,609), BRVO ($494-$13,039), and CRVO ($704-$7611); costs/line-year for DME ($60-$561), BRVO ($25-$754), and CRVO ($45-$473); and costs/QALY ($824 to $25,566). CONCLUSIONS: Relative costs and benefits should be considered in perspective when applying and developing treatment strategies.
PURPOSE: To relate costs and treatment benefits for diabetic macular edema (DME), branch retinal vein occlusion (BRVO), and central retinal vein occlusion (CRVO). DESIGN: A model of resource use, outcomes, and cost-effectiveness and utility. PARTICIPANTS: None. METHODS: Results from published clinical trials (index studies) of laser, intravitreal corticosteroids, intravitreal anti-vascular endothelial growth factor (VEGF) agents, and vitrectomy trials were used to ascertain visual benefit and clinical protocols. Calculations followed from the costs of 1 year of treatment for each treatment modality and the visual benefits as ascertained. MAIN OUTCOME MEASURES: Visual acuity (VA) saved, cost of therapy, cost per line saved, cost per line-year saved, and costs per quality-adjusted life years (QALYs). RESULTS: The lines saved for DME (0.26-2.02), BRVO (0.74-4.92), and CRVO (1.2-3.75) yielded calculations of costs/line of saved VA for DME ($1329-$11,609), BRVO ($494-$13,039), and CRVO ($704-$7611); costs/line-year for DME ($60-$561), BRVO ($25-$754), and CRVO ($45-$473); and costs/QALY ($824 to $25,566). CONCLUSIONS: Relative costs and benefits should be considered in perspective when applying and developing treatment strategies.
Authors: Lihteh Wu; J Fernando Arevalo; Maria H Berrocal; Mauricio Maia; José A Roca; Virgilio Morales-Cantón; Arturo A Alezzandrini; Manuel J Díaz-Llopis Journal: Retina Date: 2010 Jul-Aug Impact factor: 4.256
Authors: Emmett T Cunningham; Anthony P Adamis; Michael Altaweel; Lloyd P Aiello; Neil M Bressler; Donald J D'Amico; Mauro Goldbaum; David R Guyer; Barrett Katz; Manju Patel; Steven D Schwartz Journal: Ophthalmology Date: 2005-10 Impact factor: 12.079
Authors: Michael S Ip; Ingrid U Scott; Paul C VanVeldhuisen; Neal L Oden; Barbara A Blodi; Marian Fisher; Lawrence J Singerman; Michael Tolentino; Clement K Chan; Victor H Gonzalez Journal: Arch Ophthalmol Date: 2009-09
Authors: Sophie L Rogers; Rachel L McIntosh; Lyndell Lim; Paul Mitchell; Ning Cheung; Jonathan W Kowalski; Hiep P Nguyen; Jie Jin Wang; Tien Yin Wong Journal: Ophthalmology Date: 2010-06 Impact factor: 12.079
Authors: Diana Iturralde; Richard F Spaide; Catherine B Meyerle; Jay M Klancnik; Lawrence A Yannuzzi; Yale L Fisher; John Sorenson; Jason S Slakter; K Bailey Freund; Michael Cooney; Howard F Fine Journal: Retina Date: 2006-03 Impact factor: 4.256
Authors: Peter A Campochiaro; Gulnar Hafiz; Syed Mahmood Shah; Steven Bloom; David M Brown; Miguel Busquets; Thomas Ciulla; Leonard Feiner; Nelson Sabates; Kathleen Billman; Barry Kapik; Ken Green; Frances Kane Journal: Ophthalmology Date: 2010-03-03 Impact factor: 12.079
Authors: Quan Dong Nguyen; Syed Mahmood Shah; Jeffery S Heier; Diana V Do; Jennifer Lim; David Boyer; Prema Abraham; Peter A Campochiaro Journal: Ophthalmology Date: 2009-08-22 Impact factor: 12.079
Authors: Aljoscha S Neubauer; Julian Langer; Raffael Liegl; Christos Haritoglou; Armin Wolf; Igor Kozak; Florian Seidensticker; Michael Ulbig; William R Freeman; Anselm Kampik; Marcus Kernt Journal: Clin Ophthalmol Date: 2013-01-16